Source:BioSpace

The virus causes infection at all ages, especially for infants, children, old adults and immunocompromised adults, where 96% children under 5 years of age are infected by RSV.

In 2017, the WHO estimated that RSV caused around 33 million serious respiratory infections every year. This results in more than 3 million hospitalizations and nearly 60,000 deaths in children under 5 years of age every year. In 2019, the economic burden of RSV was approximately US$4.2 billion globally. However, there are no available vaccines against RSV or drugs with high efficacy for the treatment of RSV globally.

About Advaccine

Advaccine is an innovative vaccine company with a high-value prophylactic and therapeutic vaccine pipeline driven by in-house developed technology platforms and industrial manufacturing capabilities. Its pipeline consists of potential first-in-class key assets developed to address diseases caused by SARS-CoV-2, respiratory syncytial virus (RSV) and hepatitis B virus (HBV), which are diseases with huge unmet medical needs. Advaccine is also developing a series of cancer vaccine candidates, covering viral-related oncology, neoantigen-based therapeutic vaccines and tumor-associated antigen therapeutic vaccines.

Contact Advaccine:

PR@advaccine.com
IR@advaccine.com
(86)512-89188890

Cision
Cision
View original content here.

SOURCE Advaccine